Kosei Matsue

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia

Hitoshi Kiyoi, T Naoe, S Yokota et al. · Leukemia · 1997 · 342 citations

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Malignant Blood Disorder +8

Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy As Reported by the IVL Study Group in Japan

Kazuyuki Shimada, Kosei Matsue, Kazuhito Yamamoto et al. · Journal of Clinical Oncology · 2008 · 277 citations

Clinicopathologic analysis of <scp>TAFRO</scp> syndrome demonstrates a distinct subtype of <scp>HHV</scp>‐8‐negative multicentric Castleman disease

Noriko Iwaki, David C. Fajgenbaum, Christopher S. Nabel et al. · American Journal of Hematology · 2015 · 273 citations · Full text

Immunodeficiencies, Immunology, Pathology +20

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group

Lia A. Moulopoulos, Stefan Delorme, Vassilis Koutoulidis et al. · Blood Cancer Journal · 2017 · 171 citations · Full text